John Demaree has bought stock on 2 days since Dec 2018

John Demaree is a biopharma executive and corporate insider with more than 20 years of experience in oncology and hematology commercialization.( He was appointed Chief Commercial Officer at Karyopharm Therapeutics Inc. in March 2020, where he led the company’s commercial strategy and operations, including the continued commercialization of its lead oncology product XPOVIO® (selinexor), a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound.( In this role, he oversaw commercial strategy, product launches, market access, reimbursement, lifecycle management, and external commercial collaborations.( He left Karyopharm’s Chief Commercial Officer position in 2021 as part of changes to the company’s commercial leadership team.(

Before joining Karyopharm, Demaree served as Chief Commercial Officer at G1 Therapeutics, where he developed the commercial vision for the company’s oncology assets and built and led its integrated commercial function.( Earlier in his career, he held senior roles at Astellas, including Vice President, Oncology Marketing, where he established and led the oncology marketing function and contributed to the successful launch of Xtandi® (enzalutamide).( He previously led oncology business development and alliance management at Abbott and held marketing leadership positions at Novartis and Eli Lilly.( Demaree holds an MBA in Marketing and Finance and a B.S. in Marketing from the Indiana University Kelley School of Business.( As an insider, he has held equity positions in both Karyopharm Therapeutics Inc. (KPTI) and G1 Therapeutics Inc. (GTHX), reflecting his executive leadership roles in these oncology-focused companies.(

Written by Perplexity from public sources.